Vertex Moves Full Steam Ahead on Type 1 Diabetes Drug Trial With FDA's OK | BioSpace
Vertex: New Stem Cell Based Type 1 Diabetes Treatment Shown Effective in First Patient - DSM
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE
Vertex Acquires Semma Therapeutics Diabetes Research Firm
Vertex Type 1 Diabetes Research Stirs Hope for Stem Cell-Based 'Cure'
Vertex Pharmaceuticals am 52-Wochenhoch – Studie für Stammzellentherapie gegen Diabetes-Typ-1 wird fortgesetzt!
Vertex upbeat on 1st stem cell therapy for diabetes trial participant - The Niche
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte
Vertex – type 1 diabetes vs stem cell therapy - The Boar
JDRF Report: Vertex Has a New Horizon: Curing Type 1 Diabetes
FDA orders stop to Vertex diabetes study - Boston Business Journal
Can Vertex Pharmaceuticals and Douglas Melton CURE Type 1 Diabetes? | VX880 - YouTube
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech | Evaluate
Vertex to acquire ViaCyte, targeting type 1 diabetes
Vertex reports positive results for first patient in Type 1 diabetes trial - The Boston Globe
Vertex eyes type 1 diabetes cure with biotech acquisition - PMLiVE
Diabetes space continues to run hot with Vertex/ViaCyte deal - MM+M
Vertex: FDA pausiert Diabetes-Studie – Aktie unter Druck - DER AKTIONÄR
Vertex to buy Semma Therapeutics for $950m in cash
AKTIONÄR-Tipp Vertex: Übernahme – Aktie auf Jahreshoch - DER AKTIONÄR
Vertex: Trial of New Type 1 Diabetes Cell Therapy Put on Hold - DSM
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout - MedCity News
Vertex: Impressive early results for potentially curative diabetes cell therapy
A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell Therapy Pipeline
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
Vertex (VRTX) Stock Falls After FDA Pauses Diabetes Study in Surprise Move - Bloomberg
